BIRC5 and plasma cell myeloma: Specifically, the BMSC-induced drug resistance of MM cells has been associated with miR-101-3p downregulation, thus the miR-101-3p-survivin interaction can serve as a druggable target to potentially sensitize MM cells to anti-myeloma drugs [166].